Pancreatic Cancer Research

ResearcherUniversity of CincinnatiActive in the last 2 years

Sameer H. Patel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6442-1857; OpenAlex author ID A5066652338. Sources: OpenAlex.

Their work

Papers
22 (first author 6, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 6 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 22

  1. Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. First author DOI 10.1016/j.hoc.2025.07.010↗
  2. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  3. Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19990-7↗
  4. ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20039-y↗
  5. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  6. Pancreatic Ductal Adenocarcinoma Among Octogenarians: A Case for Multimodal Therapy with Appropriate Selection to Optimize Outcomes. First author DOI 10.1245/s10434-025-17249-1↗
  7. Pancreatic Cancer Screening among High-risk Individuals. First author DOI 10.1016/j.suc.2024.03.002↗
  8. Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in v… Co-author DOI 10.1007/s00109-023-02290-y↗
  9. Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00109-023-02331-6↗
  10. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  11. Radiation therapy in borderline resectable pancreatic cancer: A review. Co-author DOI 10.1016/j.surg.2021.12.013↗
  12. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Last author DOI 10.1245/s10434-022-11363-0↗
  13. ASO Author Reflections: An Underappreciated Metric: Systemic Chemotherapy Dose Density in Pancreatic Cancer. First author DOI 10.1245/s10434-022-11390-x↗
  14. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Last author DOI 10.1245/s10434-022-11580-7↗
  15. ASO Author Reflections: The Survival Advantage Persists: Benefit of Adjuvant Chemotherapy in Resected, Stage IA Pancreatic Cancer. First author DOI 10.1245/s10434-022-11650-w↗
  16. Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunoc… Last author DOI 10.3390/cancers14112618↗
  17. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. Last author DOI 10.1016/j.jss.2020.09.009↗
  18. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10075-1↗
  19. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Can… Co-author DOI 10.1097/mpa.0000000000001602↗
  20. Screening patients at high risk for pancreatic cancer-Is it time for a paradigm shift? Last author DOI 10.1002/jso.25616↗
  21. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jss.2019.01.061↗
  22. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kevin M. Turner · 8 shared papers, 2022–2025 · strength 2.27
  2. Gregory C. Wilson · 11 shared papers, 2022–2026 · strength 2.25
  3. Syed Ameen Ahmad · 13 shared papers, 2019–2025 · strength 1.83
  4. Jordan R. Kharofa · 7 shared papers, 2020–2026 · strength 1.21
  5. Olugbenga Olanrele Olowokure · 7 shared papers, 2020–2026 · strength 1.21
  6. Davendra P. S. Sohal · 5 shared papers, 2022–2026 · strength 0.97
  7. Syed A. Ahmad · 3 shared papers, 2026 · strength 0.71
  8. Syed Arif Ahmad · 2 shared papers, 2023–2026 · strength 0.68
  9. Ryan P. Johnson · 2 shared papers, 2026 · strength 0.53
  10. Paul H. McClelland · 2 shared papers, 2026 · strength 0.53
  11. Erich Gulbins · 3 shared papers, 2022–2023 · strength 0.48
  12. Ildikò Szabó · 3 shared papers, 2022–2023 · strength 0.48
  13. Matthew H. G. Katz · 2 shared papers, 2021–2023 · strength 0.34
  14. Giuseppe Malleo · 2 shared papers, 2023–2026 · strength 0.31
  15. Ryan K. Schmocker · 2 shared papers, 2023–2026 · strength 0.31
  16. Jin Peng He · 2 shared papers, 2023–2026 · strength 0.31
  17. Russell F. Palm · 2 shared papers, 2023–2026 · strength 0.31
  18. Dilmurodjon Eshmuminov · 2 shared papers, 2023–2026 · strength 0.31
  19. Víctor López‐López · 2 shared papers, 2023–2026 · strength 0.31
  20. Elena B. Rangelova · 2 shared papers, 2023–2026 · strength 0.31
  21. Sarah E. Hoffe · 2 shared papers, 2023–2026 · strength 0.31
  22. Changhoon Yoo · 2 shared papers, 2023–2026 · strength 0.31
  23. Daniel Erik Abbott · 2 shared papers, 2019–2025 · strength 0.27
  24. Sharon Marie Weber · 2 shared papers, 2019–2025 · strength 0.27
  25. Nipun B. Merchant · 2 shared papers, 2019–2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.